Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long‐Term Response to Atrasentan in Patients With Diabetic Kidney Disease
暂无分享,去创建一个
J. McMurray | H. Parving | G. Bakris | V. Perkovic | D. Kitzman | D. de Zeeuw | H. Heerspink | G. Mayer | D. Kohan | P. Rossing | D. Zeeuw | F. Hou | H. Makino | M. Nowicki | S. Tobe | R. Correa-Rotter | J. D. Smeijer | Jeroen V. Koomen | H. Heerspink
[1] A. Voors,et al. Renal Compression in Heart Failure: The Renal Tamponade Hypothesis. , 2022, JACC. Heart failure.
[2] J. McMurray,et al. Individual Atrasentan Exposure is Associated With Long‐term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease , 2020, Clinical pharmacology and therapeutics.
[3] J. McMurray,et al. Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial , 2020, Diabetes, obesity & metabolism.
[4] M. Taal. Review for "Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: a post‐hoc analysis of the SONAR trial" , 2020 .
[5] T. Lehr,et al. Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor Antagonists , 2019, Pharmaceutical Research.
[6] Debra F. Weinstein,et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. , 2019, Lancet.
[7] A. Israni,et al. Genome-wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian kidney transplant recipients , 2017, The Pharmacogenomics Journal.
[8] J. McMurray,et al. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy , 2018, Diabetes, obesity & metabolism.
[9] Wei Zhang,et al. Identification of two novel genes SLC15A2 and SLCO1B3 associated with maintenance dose variability of warfarin in a Chinese population , 2017, Scientific Reports.
[10] R. Ho,et al. Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1) , 2017, British journal of clinical pharmacology.
[11] H. Parving,et al. Comparison of exposure response relationship of atrasentan between North American and Asian populations , 2017, Diabetes, obesity & metabolism.
[12] Musa A. Ahmed,et al. Polymorphism in Endothelin-1 Gene: An Overview. , 2016, Current clinical pharmacology.
[13] G. Navis,et al. Improving the efficacy of RAAS blockade in patients with chronic kidney disease , 2013, Nature Reviews Nephrology.
[14] H. Cardinal,et al. Influence of SLCO1B3 genetic variations on tacrolimus pharmacokinetics in renal transplant recipients. , 2013, Drug metabolism and pharmacokinetics.
[15] C. Rotimi,et al. UGT1A1 is a major locus influencing bilirubin levels in African Americans , 2011, European Journal of Human Genetics.
[16] G. Rosner,et al. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. , 2012, Genome research.
[17] W. Haefeli,et al. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro , 2011, Cancer Chemotherapy and Pharmacology.
[18] T. Shuto,et al. Pharmacokinetic Impact of SLCO1A2 Polymorphisms on Imatinib Disposition in Patients With Chronic Myeloid Leukemia , 2011, Clinical pharmacology and therapeutics.
[19] A. Y. Lu,et al. Pharmacogenetics, Pharmacogenomics, and Individualized Medicine , 2011, Pharmacological Reviews.
[20] P. Neuvonen,et al. Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake , 2011, Pharmacological Reviews.
[21] Tae-Wook Kang,et al. Genome-wide association of serum bilirubin levels in Korean population. , 2010, Human molecular genetics.
[22] L. Ruilope,et al. Avosentan for overt diabetic nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.
[23] A. Martinho,et al. Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients. , 2009, Transplantation proceedings.
[24] P. Neuvonen,et al. Global analysis of genetic variation in SLCO1B1. , 2008, Pharmacogenomics.
[25] Mikko Niemi,et al. Role of OATP transporters in the disposition of drugs. , 2007, Pharmacogenomics.
[26] C. Locke,et al. Dual Effects of Rifampin on the Pharmacokinetics of Atrasentan , 2007, Journal of clinical pharmacology.
[27] P. Mahadevan,et al. An overview , 2007, Journal of Biosciences.
[28] Mikko Niemi,et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid , 2006, Pharmacogenetics and genomics.
[29] R. Kim,et al. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics , 2006, Clinical pharmacology and therapeutics.
[30] D Lindhout,et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. , 1995, The New England journal of medicine.